Current Headlines

  1. Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Clinical Trial Data

    Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases recently announced that data from the Company’s Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting

  2. Quanterix’ Simoa Technology To Broaden RayBiotech Immunoassay Services

    Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, recently announced that RayBiotech, Inc., of Norcross, GA, has adopted its Simoa technology to deploy as part of their innovative solutions for biomarker discovery and testing

  3. X-Chem And Navitor Pharmaceuticals Enter Into License Agreement On Novel Small Molecules Targeting mTORC1 Activation

    X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, recently announced that Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive license to a series of small molecules targeting the activation of mTORC1, a key protein complex that orchestrates nutrient-mediated cellular metabolism and growth

  4. MOVANTIK (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US

    AstraZeneca announced recently that MOVANTIK (naloxegol) has launched in the United States

  5. BRILINTA Receives US FDA Approval For New Administration Option

    AstraZeneca recently announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow BRILINTA 90 mg tablets whole

  6. Certara Supported Risk Assessment Research Wins Outstanding Paper Award

    Certara, the global biosimulation technology-enabled drug development and drug safety consulting company, recently announced that the Toxicological Sciences article, entitled “Incorporating Population Variability and Susceptible Subpopulations into Dosimetry for High-throughput Toxicity Testing,” using its Simcyp Simulator, has been selected by the Risk Assessment Specialty Section (RASS) of the Society of Toxicology (SOT) as its “Best Published Paper Advancing the Science of Risk Assessment

  7. Asahi Kasei Pharma Selects Evotec As Its Partner For Ion Channel Drug Discovery

    Evotec AG recently announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Under the terms of the agreement, Evotec will use its world-class ion channel platform to identify inhibitors of multiple ion channel targets

  8. Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302

    Therapure Innovations, a division of Therapure Biopharma Inc., recently announces that the U.S. Food and Drug Administration (FDA) has given the company approval to proceed with a Phase 1 clinical trial of TBI 302, a targeted therapeutic for the treatment of liver cancer

  9. Takeda Licenses Rights To Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology

    Takeda Pharmaceutical Company Limited and ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology, recently announced that Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – including ImmunoGen’s new DNA-acting IGN payload agents – to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets

  10. Baxter BioScience Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophilia A And B Patients With Inhibitors

    Baxter International Inc. recently announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.